# Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

> **NCT03469934** · PHASE2 · COMPLETED · sponsor: **AnaptysBio, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Eosinophilic Asthma

## Interventions

- **BIOLOGICAL:** Etokimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03469934
- **Lead sponsor:** AnaptysBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-10-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469934, "Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03469934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*